These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31807100)

  • 1. Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study.
    Ebadi Fardazar F; Sarabi Asiabar A; Safari H; Asgari M; Saber A; Ebadi Fard Azar AA
    Risk Manag Healthc Policy; 2019; 12():199-208. PubMed ID: 31807100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facilitators of improving the function of nongovernmental organizations (NGOs) in Iran's health system.
    Rajabi M; Ebrahimi P; Aryankhesal A
    J Educ Health Promot; 2023; 12():147. PubMed ID: 37404908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Study of Comparative Advantage and Intra-Industry Trade in the Pharmaceutical Industry of Iran.
    Yusefzadeh H; Rezapour A; Lotfi F; Ebadifard Azar F; Nabilo B; Abolghasem Gorji H; Hadian M; Shahidisadeghi N; Karami A
    Glob J Health Sci; 2015 Apr; 7(6):295-307. PubMed ID: 26153184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of nongovernmental organizations in Iran's health system: What do they do and what can they do?
    Rajabi M; Ebrahimi P; Aryankhesal A
    J Educ Health Promot; 2022; 11():101. PubMed ID: 35573612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Structure of the World Pharmaceutical Market: Prioritizing Iran's Target Export Markets.
    Shabaninejad H; Yusefzadeh H; Mehralian G; Rahimi B
    Iran J Pharm Res; 2019; 18(1):546-555. PubMed ID: 31089388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Study of Effective Factors on Iran's Pharmaceutical Export Supply and Demand.
    Najafi B; Mahboub-Ahari A; Nouraei Motlagh S; Otobideh SA; Rahimi B; Shabaninejad H; Yusefzadeh H
    Iran J Pharm Res; 2019; 18(4):2226-2232. PubMed ID: 32184887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenge of Politico-Economic Sanctions on Pharmaceutical Procurement in Iran: A Qualitative Study.
    Bastani P; Dehghan Z; Kashfi SM; Dorosti H; Mohammadpour M; Mehralian G
    Iran J Med Sci; 2022 Mar; 47(2):152-161. PubMed ID: 35291429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Factors Associated With Iran's Intra-Industry Trade in Pharmaceuticals.
    Yusefzadeh H; Hadian M; Abolghasem Gorji H; Ghaderi H
    Glob J Health Sci; 2015 Mar; 7(5):311-9. PubMed ID: 26156931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic analysis of Iran's climate resilient health system.
    Mosadeghrad AM; Afshari M; Dehnavi H; Keliddar I; Zahmatkesh M; Isfahani P; Sharifi T; Shahsavani A; Ostadtaghizadeh A; Abbasabadi-Arab M; Yunesian M
    BMC Health Serv Res; 2024 Sep; 24(1):1149. PubMed ID: 39350069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Policies and measures implemented to reduce the impact of international sanctions on Iran's pharmaceutical sector.
    Emami F; Cheraghali AM
    Res Pharm Sci; 2022 Jun; 17(3):274-283. PubMed ID: 35531135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining the effective factors on developing entrepreneurial managers in the Iranian health system: A qualitative study.
    Farajzadeh F; Tourani S; Shabaninejad H
    J Educ Health Promot; 2021; 10():471. PubMed ID: 35233418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying the Challenges of Iran's Health Houses and Presenting a Solution.
    Saberi SH; Alimehr M; Amiresmaili M; Seyednezhad M
    Electron Physician; 2016 Oct; 8(10):3122-3126. PubMed ID: 27957313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donors' Participation in Iran's Health System: Challenges and Solutions.
    Mosadeghrad AM; Tajvar M; Ehteshami F
    Int J Health Policy Manag; 2022 Dec; 11(11):2514-2524. PubMed ID: 35120403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
    Coghlan R; Stephens P; Mwale B; Siyanga M
    Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2012-2025 Roadmap of I.R.Iran's Disaster Health Management.
    Ardalan A; Rajaei MH; Masoumi G; Azin A; Zonoobi V; Sarvar M; Vaskoei Eshkevari K; Ahmadnezhad E; Jafari G
    PLoS Curr; 2012 Jul; 4():e4f93005fbcb34. PubMed ID: 22953239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Explaining the challenges of resources management and its underlying factors in COVID-19 era in Iran: a qualitative study.
    Vatandoost V; Tabatabaee SS; Okhovati M; Barooni M
    BMC Public Health; 2023 Oct; 23(1):2118. PubMed ID: 37891547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The trend of change in the role of pre-hospital emergency medical services in Iran's healthcare system: a situational analysis.
    Miri K; Sabbaghi M; Mazlum SR; Namazinia M
    BMC Emerg Med; 2023 Aug; 23(1):99. PubMed ID: 37648986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physical rehabilitation in Iran after international sanctions: explored findings from a qualitative study.
    Shahabi S; Teymourlouy AA; Shabaninejad H; Kamali M; Lankarani KB; Mojgani P
    Global Health; 2020 Sep; 16(1):86. PubMed ID: 32967707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surprising decline in Iran's growth rates.
    Roudi F
    Popul Today; 1997 Nov; 25(11):4. PubMed ID: 12321257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.